CRL

Charles River Laboratories International, Inc. NYSE

Healthcare ·Medical - Diagnostics & Research ·US · criver.com

$165.78

After hrs $172.32 -0.02%

Mkt Cap $8.2B

52w Low $113.89 45.1% of range 52w High $228.88

50d MA $169.34 200d MA $175.83

P/E (TTM) -57.0x

EV/EBITDA 14.2x

P/B 2.6x

Debt/Equity 1.0x

ROE -4.6%

P/FCF 19.5x

RSI (14) —

ATR (14) —

Beta 1.62

50d MA $169.34

200d MA $175.83

Avg Volume 1.0M

About

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufactu…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 18, 2026	AMC	2.33	2.39	+2.6%	158.00	-2.5%	+3.9%	+6.9%	+3.5%	+5.1%	+6.1%	-2.8%	—
Nov 5, 2025	AMC	2.32	2.43	+4.7%	167.70	+0.0%	+1.9%	+0.2%	+0.8%	+3.5%	+2.3%	+9.9%	—
Aug 6, 2025	AMC	2.50	3.12	+24.8%	150.33	+2.0%	-0.4%	-1.1%	-0.9%	+1.6%	+3.1%	+9.1%	—
May 7, 2025	AMC	2.06	2.34	+13.6%	136.97	+2.7%	+3.2%	+1.3%	+4.5%	+5.1%	+1.4%	+5.6%	—
Feb 19, 2025	AMC	2.50	2.66	+6.4%	165.00	+0.0%	-1.7%	-1.2%	+3.3%	+1.3%	+1.8%	+1.4%	—
Nov 6, 2024	AMC	2.42	2.59	+7.0%	214.20	+0.7%	-1.8%	+0.6%	+3.0%	+0.8%	-3.6%	-10.5%	—
Aug 7, 2024	AMC	2.39	2.80	+17.2%	199.96	-4.2%	+1.0%	+0.5%	-2.8%	+1.8%	-0.7%	-6.0%	—
May 9, 2024	AMC	2.06	2.27	+10.2%	230.09	+0.1%	-0.9%	-0.7%	+1.2%	+1.1%	-2.3%	-6.8%	—
Feb 14, 2024	AMC	2.39	2.46	+2.9%	245.12	-1.2%	+0.1%	-0.1%	-2.5%	-1.6%	+0.7%	+5.7%	—
Nov 8, 2023	AMC	2.35	2.72	+15.7%	175.97	+0.7%	-3.7%	-2.3%	-3.4%	+1.4%	+6.6%	+16.2%	—
Aug 9, 2023	AMC	2.63	2.69	+2.3%	215.80	+0.1%	+0.8%	-0.6%	+0.5%	-2.7%	-6.4%	-7.4%	—
May 11, 2023	AMC	2.59	2.78	+7.3%	195.75	+0.6%	-2.3%	-1.7%	-3.9%	+0.5%	+1.8%	+5.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 14	Barclays	Maintains	Overweight → Overweight	—	$178.34	$181.90	+2.0%	+0.5%	+1.2%	-0.8%	+3.1%	+4.0%
Apr 13	JP Morgan	Maintains	Neutral → Neutral	—	$175.65	$177.47	+1.0%	+1.5%	+2.1%	+2.8%	+0.7%	+4.7%
Feb 25	UBS	Maintains	Neutral → Neutral	—	$166.06	$169.91	+2.3%	+0.9%	+5.7%	+7.5%	+7.6%	+5.8%
Feb 20	TD Cowen	Maintains	Buy → Buy	—	$164.24	$162.54	-1.0%	+2.8%	-0.4%	+1.1%	+2.0%	+6.8%
Feb 20	Mizuho	Maintains	Neutral → Neutral	—	$164.24	$162.54	-1.0%	+2.8%	-0.4%	+1.1%	+2.0%	+6.8%
Feb 19	Evercore ISI	Maintains	Outperform → Outperform	—	$158.00	$154.09	-2.5%	+3.9%	+6.9%	+3.5%	+5.1%	+6.1%
Feb 19	Barclays	Maintains	Overweight → Overweight	—	$158.00	$154.09	-2.5%	+3.9%	+6.9%	+3.5%	+5.1%	+6.1%
Jan 16	Citigroup	Maintains	Buy → Buy	—	$223.47	$223.43	-0.0%	-1.7%	-2.4%	+1.5%	+0.3%	-1.7%
Jan 13	Evercore ISI	Maintains	Outperform → Outperform	—	$218.82	$221.66	+1.3%	+0.1%	-1.1%	+2.1%	+0.4%	-0.3%
Dec 18	Mizuho	Maintains	Neutral → Neutral	—	$195.98	$197.32	+0.7%	-1.1%	+0.6%	+3.6%	+3.5%	+3.7%
Dec 15	JP Morgan	Maintains	Neutral → Neutral	—	$193.03	$197.08	+2.1%	+2.7%	+1.1%	+1.5%	+0.4%	+2.1%
Dec 15	Barclays	Maintains	Overweight → Overweight	—	$193.03	$197.08	+2.1%	+2.7%	+1.1%	+1.5%	+0.4%	+2.1%
Nov 11	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$168.97	$169.70	+0.4%	+2.7%	+1.5%	+0.1%	-0.7%	-3.7%
Nov 10	TD Cowen	Maintains	Buy → Buy	—	$168.05	$167.14	-0.5%	+0.5%	+3.2%	+2.1%	+0.7%	-0.1%
Nov 6	Barclays	Maintains	Overweight → Overweight	—	$167.70	$167.72	+0.0%	+1.9%	+0.2%	+0.8%	+3.5%	+2.3%
Nov 6	JP Morgan	Maintains	Neutral → Neutral	—	$167.70	$167.72	+0.0%	+1.9%	+0.2%	+0.8%	+3.5%	+2.3%
Nov 6	Baird	Upgrade	Neutral → Outperform	—	$167.70	$167.72	+0.0%	+1.9%	+0.2%	+0.8%	+3.5%	+2.3%
Oct 17	Mizuho	Maintains	Neutral → Neutral	—	$174.95	$173.16	-1.0%	+2.0%	+5.3%	+7.6%	+6.9%	+9.2%
Oct 6	William Blair	Upgrade	Market Perform → Outperform	—	$177.33	$178.15	+0.5%	-1.3%	-4.1%	-2.2%	-2.9%	-5.8%
Oct 3	Evercore ISI	Maintains	Outperform → Outperform	—	$175.36	$176.00	+0.4%	+1.1%	-0.2%	-3.0%	-1.1%	-1.8%
Oct 2	Barclays	Upgrade	Equal Weight → Overweight	—	$170.48	$173.25	+1.6%	+2.9%	+4.0%	+2.6%	-0.2%	+1.8%
Sep 9	Jefferies	Upgrade	Hold → Buy	—	$162.00	$167.50	+3.4%	-2.9%	-5.4%	-1.4%	-5.6%	-6.0%
Aug 8	Evercore ISI	Maintains	Outperform → Outperform	—	$149.78	$150.49	+0.5%	-0.7%	-0.6%	+2.0%	+3.5%	+4.0%
Aug 7	Barclays	Maintains	Equal Weight → Equal Weight	—	$150.33	$153.37	+2.0%	-0.4%	-1.1%	-0.9%	+1.6%	+3.1%
Aug 7	JP Morgan	Maintains	Neutral → Neutral	—	$150.33	$153.37	+2.0%	-0.4%	-1.1%	-0.9%	+1.6%	+3.1%
Jul 9	Evercore ISI	Maintains	Outperform → Outperform	—	$158.39	$162.89	+2.8%	+0.4%	+3.3%	+0.6%	-0.2%	-2.5%
Jul 9	Citigroup	Upgrade	Neutral → Buy	—	$158.39	$162.89	+2.8%	+0.4%	+3.3%	+0.6%	-0.2%	-2.5%
May 23	Redburn Atlantic	Upgrade	Neutral → Buy	—	$135.60	$134.21	-1.0%	+0.8%	+2.2%	+0.5%	+1.5%	+0.0%
May 8	Baird	Maintains	Neutral → Neutral	—	$136.97	$140.70	+2.7%	+3.2%	+1.3%	+4.5%	+5.1%	+1.4%
May 8	Barclays	Maintains	Equal Weight → Equal Weight	—	$136.97	$140.70	+2.7%	+3.2%	+1.3%	+4.5%	+5.1%	+1.4%
Apr 10	Barclays	Maintains	Equal Weight → Equal Weight	—	$139.07	$136.27	-2.0%	-28.1%	-28.3%	-23.3%	-23.8%	-25.0%
Apr 9	Mizuho	Maintains	Neutral → Neutral	—	$123.61	$121.71	-1.5%	+12.5%	-19.1%	-19.3%	-13.8%	-14.3%
Mar 21	Goldman Sachs	Downgrade	Buy → Neutral	—	$165.35	$162.94	-1.5%	+1.2%	+1.0%	-2.4%	-4.3%	-4.4%
Mar 4	Citigroup	Upgrade	Sell → Neutral	—	$163.50	$164.07	+0.3%	+0.5%	+2.5%	+3.5%	+7.6%	+7.1%
Mar 3	Redburn Atlantic	Upgrade	Sell → Neutral	—	$165.31	$165.89	+0.4%	-1.1%	-0.6%	+1.4%	+2.4%	+6.4%
Feb 20	JP Morgan	Maintains	Neutral → Neutral	—	$165.00	$165.00	+0.0%	-1.7%	-1.2%	+3.3%	+1.3%	+1.8%
Feb 20	Baird	Maintains	Neutral → Neutral	—	$165.00	$165.00	+0.0%	-1.7%	-1.2%	+3.3%	+1.3%	+1.8%
Feb 20	Barclays	Maintains	Equal Weight → Equal Weight	—	$165.00	$165.00	+0.0%	-1.7%	-1.2%	+3.3%	+1.3%	+1.8%
Feb 18	Barclays	Maintains	Equal Weight → Equal Weight	—	$151.99	$151.59	-0.3%	+1.6%	+8.6%	+6.8%	+7.3%	+12.2%
Feb 5	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$163.12	$165.84	+1.7%	+1.7%	+1.9%	+0.4%	-2.0%	-5.0%
Feb 3	JP Morgan	Maintains	Neutral → Neutral	—	$164.76	$161.80	-1.8%	-1.9%	-1.0%	+0.7%	+0.9%	-0.6%
Jan 23	Goldman Sachs	Maintains	Buy → Buy	—	$168.22	$168.90	+0.4%	-0.8%	-1.9%	-1.4%	-2.7%	-3.9%
Jan 22	William Blair	Downgrade	Outperform → Market Perform	—	$169.81	$167.87	-1.1%	-0.9%	-1.7%	-2.9%	-2.3%	-3.6%
Jan 17	UBS	Downgrade	Buy → Neutral	—	$165.80	$165.41	-0.2%	-1.4%	+2.4%	+1.5%	+0.6%	-0.5%
Jan 14	William Blair	Maintains	Outperform → Outperform	—	$190.14	$179.87	-5.4%	-6.3%	-8.5%	-12.8%	-14.0%	-10.7%
Dec 16	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$190.46	$189.72	-0.4%	-0.2%	-0.6%	-3.8%	-4.4%	-2.5%
Dec 13	BofA Securities	Maintains	Neutral → Neutral	—	$194.27	$194.17	-0.1%	-2.0%	-2.2%	-2.5%	-5.7%	-6.2%
Nov 11	TD Cowen	Maintains	Hold → Hold	—	$215.39	$217.67	+1.1%	+2.5%	+0.3%	-4.1%	-8.6%	-12.8%
Nov 7	Evercore ISI	Maintains	In Line → In Line	—	$214.20	$215.75	+0.7%	-1.8%	+0.6%	+3.0%	+0.8%	-3.6%
Nov 7	UBS	Maintains	Buy → Buy	—	$214.20	$215.75	+0.7%	-1.8%	+0.6%	+3.0%	+0.8%	-3.6%

Recent Filings

8-K · 7.01 ! Medium

Charles River Laboratories International, Inc. -- 8-K 7.01: Regulation FD Disclosure

Charles River Laboratories plans to divest its CDMO and Cell Solutions businesses, eliminating revenue streams from advanced therapy manufacturing services and cellular materials, potentially impacting investor returns.

Feb 25

8-K

Charles River Laboratories International, Inc. -- 8-K Filing

Charles River Laboratories' Q4 2025 revenue declined 0.8% year-over-year to $994.2 million, signaling modest top-line pressure that investors should monitor alongside management's 2026 guidance.

Feb 18

8-K · 5.02 !!! Very High

Charles River Laboratories International, Inc. -- 8-K 5.02: Executive Change

Charles River Laboratories appointed Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer, effective April 6, 2026, signaling leadership stability in financial operations.

Feb 18

Data updated apr 25, 2026 3:15am · Source: massive.com